Replies to post #145780 on Biotech Values

[mcbio]

Well, I like EnVivo's trials better due to the ability to see dose related responses especially in AD trial - their schizophrenia trial was more mixed in this regard. TRGT used one single dose titration schedule, result wasn't clear cut, no surprise AZN declined.

Yes, but TRGT hasn't tested their alpha-7 candidate in AD like EnVivo, just ADHD and schizophrenia to date. Hopefully the EnVivo data bodes well for TRGT's chances with its drug in AD down the road as well.

Roche bought Memory Pharmaceuticals several years ago at least in part for their alpha 7 program. I need to do some DD to see where that program is.